Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Oct-01-02 | Dec-31-01 | Dec-31-00 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Core Chemistry | 1,140.1 | 1,074.8 | 1,005.6 | 903.7 | | | 732.8 | |
| Hemostasis | 316.7 | 298.7 | 276.7 | 237.0 | | | 174.4 | |
| Microbiology | 166.1 | 164.8 | 152.5 | 150.5 | | | 128.1 | |
| Infectious Disease | 89.4 | 86.4 | 84.0 | 78.9 | | | 63.0 | |
| Other | 26.9 | 33.4 | 41.0 | 66.3 | | | 134.1 | |
| Total revenues | 1,739.2 | 1,658.1 | 1,559.8 | 1,436.4 | 347.1 | 934.4 | 1,232.4 | 1,183.7 |
| Revenue growth [+] | 4.9% | 6.3% | 8.6% | 313.8% | -71.8% | | 4.1% | |
| Core Chemistry | 6.1% | 6.9% | 11.3% | | | | | |
| Hemostasis | 6.0% | 8.0% | 16.8% | | | | | |
| Microbiology | 0.8% | 8.1% | 1.3% | | | | | |
| Infectious Disease | 3.5% | 2.9% | 6.5% | | | | | |
| Mature Products/Other | -19.5% | -18.5% | -38.2% | | | | | |
| Cost of goods sold | 788.1 | 741.3 | 704.8 | 678.2 | 228.8 | 467.5 | 595.6 | 583.4 |
| Gross profit | 951.1 | 916.8 | 855.0 | 758.2 | 118.3 | 466.9 | 636.8 | 600.3 |
| Gross margin | 54.7% | 55.3% | 54.8% | 52.8% | 34.1% | 50.0% | 51.7% | 50.7% |
| Selling, general and administrative | 565.4 | 548.6 | 529.2 | 493.9 | 124.5 | 322.9 | 432.3 | 470.8 |
| Research and development | 160.7 | 141.5 | 134.0 | 117.5 | 28.8 | 65.3 | 83.7 | 103.3 |
| Other operating expenses | | | | | 2.2 | 38.3 | 20.1 | 24.2 |
| EBITDA [+] | 385.4 | 389.7 | 344.6 | 283.5 | -6.9 | 126.9 | 221.5 | 101.2 |
| EBITDA growth | -1.1% | 13.1% | 21.6% | -4208.7% | -103.1% | | 118.9% | |
| EBITDA margin | 22.2% | 23.5% | 22.1% | 19.7% | -2.0% | 13.6% | 18.0% | 8.5% |
| Depreciation | 160.4 | 163.0 | 152.8 | 136.7 | 30.3 | 86.5 | 111.9 | 94.2 |
| EBITA | 225.0 | 226.7 | 191.8 | 146.8 | -37.2 | 40.4 | 109.6 | 7.0 |
| EBITA margin | 12.9% | 13.7% | 12.3% | 10.2% | -10.7% | 4.3% | 8.9% | 0.6% |
| Amortization of intangibles | | | | | | | 8.9 | 5.0 |
| EBIT [+] | 225.0 | 226.7 | 191.8 | 146.8 | -37.2 | 40.4 | 100.7 | 2.0 |
| EBIT growth | -0.7% | 18.2% | 30.7% | -494.6% | -136.9% | | 4935.0% | |
| EBIT margin | 12.9% | 13.7% | 12.3% | 10.2% | -10.7% | 4.3% | 8.2% | 0.2% |
| Non-recurring items | 21.3 | | | -0.9 | -2.2 | -38.2 | 12.2 | 25.3 |
| Interest expense, net [+] | 22.7 | 39.2 | 61.6 | 74.7 | -0.9 | -2.7 | -6.0 | -3.0 |
| Interest expense | 26.9 | 43.5 | 64.0 | 77.8 | | | | |
| Interest income | 4.2 | 4.3 | 2.4 | 3.1 | 0.9 | 2.7 | 6.0 | 3.0 |
| Other income (expense), net | -2.8 | -22.8 | -9.8 | 1.3 | -15.9 | 1,449.9 | -187.8 | -142.3 |
| Pre-tax income | 178.2 | 164.7 | 120.4 | 74.3 | -50.0 | 1,531.2 | -93.3 | -162.6 |
| Income taxes | 58.2 | 39.8 | 40.5 | 26.2 | -1.4 | 20.1 | 8.4 | 363.2 |
| Tax rate | 32.7% | 24.2% | 33.6% | 35.3% | 2.8% | 1.3% | | |
| Net income | 120.0 | 124.9 | 79.9 | 48.1 | -48.6 | 1,531.1 | -101.7 | -532.6 |
| Net margin | 6.9% | 7.5% | 5.1% | 3.3% | -14.0% | 163.9% | -8.3% | -45.0% |
| |
| Basic EPS [+] | $1.39 | $1.41 | $0.93 | $0.60 | | | | |
| Growth | -1.4% | 51.6% | 55.0% | | | | | |
| Diluted EPS [+] | $1.36 | $1.36 | $0.88 | $0.57 | | | | |
| Growth | 0.0% | 54.5% | 54.4% | | | | | |
| |
| Shares outstanding (basic) [+] | 86.3 | 88.6 | 85.9 | 80.2 | | | | |
| Growth | -2.5% | 3.1% | 7.2% | | | | | |
| Shares outstanding (diluted) [+] | 88.2 | 91.8 | 90.8 | 84.4 | | | | |
| Growth | -3.9% | 1.1% | 7.6% | | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|